



Bipolar Disorder and Suicide: a Review

Jacob N. Miller¹ · Donald W. Black²

Published online: 18 January 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

Purpose of Review Bipolar disorder has the highest rate of suicide of all psychiatric conditions and is approximately 20–30 times that of the general population. The purpose of this review is to discuss findings relevant to bipolar disorder and suicide.

Recent Findings Risk factors include male gender, living alone, divorced, no children, Caucasian, younger age (< 35 years), elderly age (> 75 years), unemployment, and a personal history of suicide attempt and family history of suicide attempt or suicide completion, as well as predominant depressive polarity. Suicide is associated with the depressed or mixed subtypes, not mania. Although there are emerging treatments for bipolar depression, such as ketamine and TMS, lithium remains the only medication associated with lowered suicide rates in bipolar disorder.

Summary Understanding clinical and demographic risk factors for suicide in bipolar disorder remains the best way to prevent suicidal behavior. Early intervention and treatment with anti-suicidal medications, such as lithium, along with close observation and follow-up is the best way to mitigate suicide in patients with bipolar disorder.

Keywords Bipolar disorder · Suicide · Suicide attempt · Suicide completion · Suicide risk factors

Introduction

Bipolar disorder is a chronic mood disorder characterized by manic or hypomanic episodes alternating or intermixed with episodes of depression [1, 2]. The 12-month prevalence of DSM-IV bipolar disorder in the USA was estimated at 0.6%, with a lifetime prevalence of over 1% of the world's population, irrespective of nationality, ethnic origin, or socioeconomic status [3, 4]. The total prevalence of bipolar disorder could be as high as 5% if bipolar II and cyclothymia are included [5, 6]. Bipolar disorder tends to affect men more than women, with a lifetime male-to-female prevalence ratio of 1.1:1 [4]. The strongest and most consistent risk factor for bipolar disorder is having a positive family history of bipolar disorder, increasing in magnitude with degree of kinship.

This article is part of the Topical Collection on *Bipolar Disorders*

✉ Donald W. Black
donald-black@uiowa.edu

¹ University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA

² Department of Psychiatry, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 2-126b Medical Education Building, Iowa City, IA 52242, USA

Bipolar disorder is a lifelong episodic illness with a variable course that can lead to functional, occupational, and cognitive impairments [1, 7, 8]. There are significant costs associated with this disorder, which include the direct costs of treatment, and the much greater indirect costs of decreased productivity, excess unemployment, and excess mortality [9]. The high rates of mortality are due to natural causes such as cardiovascular disease and diabetes, as well as suicide, which is a key contributor to the high mortality rate. Quality of life is also markedly impaired in patients with bipolar disorder, even when clinically euthymic, and especially with a history of previous suicide attempt [10, 11–13].

Both DSM-5 and the International Classification of Diseases (ICD-10) [14] recognize bipolar I and bipolar II disorders. For bipolar I disorder, at least one manic episode must have occurred, and, although major depressive episodes are typical, they are not required for the diagnosis. For bipolar II disorder, at least one hypomanic episode and one major depressive episode are required for the diagnosis [2]. Only 20% of patients with bipolar disorder having a major depressive episode are diagnosed with bipolar disorder within the first year of treatment, and the mean delay of diagnosis is 5–10 years from illness onset [15, 16].

Patients with mood disorders are at very high risk of death by suicide compared to the general population. Patients with

bipolar disorder are at an even greater risk of suicide, with approximately 20–30-fold increase than the general population.

Suicide in the General Population

Worldwide, about 800,000 to 1 million deaths per year are due to suicide [17], and it is estimated that 1.5 million will die from suicide in 2020. In developed countries, this equates to a suicide rate of $0.014\% \pm 0.007\%$ per year [14/100000 person per year \pm standard deviation (SD)] in general populations (Table 1) [18–24]. Suicide is a tremendous challenge for healthcare professionals and society at large. It is one of the top 10 leading causes of death worldwide, and in certain countries is the second leading cause of death in the 15–34 age group [18]. There are many risk factors for suicide in the general population and for mood disorders in particular. However, disease-specific risk factors for bipolar disorder have been more difficult to identify. Over the past few decades, studies investigating suicide risk factors in bipolar disorder have had mixed results. Risk factors for suicide in the general population include (1) male gender, (2) living alone, (3) divorced, (4) no children, (5) Caucasian, (6) younger age (<35 years), (7) elderly age (>75 years), and (8) unemployment [25]. Understanding the risk factors for suicide in bipolar disorder is essential for treatment planning, risk mitigation, prognosis, clinical research, and drug development.

Bipolar Disorder and Suicide

Bipolar disorder carries the highest risk of suicide compared to all other psychiatric illnesses [10•, 26–33]. However, suicide rates in bipolar disorder have been reported inconsistently when considering bipolar subtypes, gender, age, or illness severity. Although studies have differed on the relative rates of suicide in bipolar disorder patients compared to the general population, it is estimated that the annual risk of attempts is 400–1400/100,000, or approximately 0.9%, which equates to a 30- to 60-fold higher risk than the general population (Table 1) [23, 24]. In other words, about one-third to one-half of bipolar patients attempt suicide at least once in their

lifetime and approximately 15–20% die due to suicide [5, 24, 34]. Bipolar disorder patients with prior suicide attempts also have a worse quality of life than bipolar patients without prior attempts [11].

The Bipolar Suicide

Clinical Features

Suicide risk in bipolar disorder varies depending on illness characteristics and phase of illness. Suicide attempts are much more common at the onset of illness during the first depressive episode and early in the course of illness rather than later on [24, 35]. Suicidal behavior is primarily associated with depressed and mixed phases of illness. Major depressive episodes are associated with the highest risk of suicide, followed by mixed episodes, and finally manic episodes, which are associated with the lowest risk of suicide. Patients with rapid cycling bipolar disorder are also at a higher risk compared to non-rapid cyclers. Suicide risk increases among bipolar patients with a longer duration of illness, and a longer duration of untreated illness. This finding is attributed to a higher frequency and duration of depression [36].

Bipolar disorder patients spend approximately half of their life symptomatic, mostly with depressed episodes or subsyndromal depressive symptoms, thereby increasing the risk of suicide. The predominant polarity of illness can be used to predict suicidal risk, with predominant-depression carrying the highest risk of suicide [5, 37–40]. Mixed-states with predominant depression also have a markedly increased association with suicide [5]. The predominant polarity of the initial episode of bipolar disorder can also be used to predict the polarity of subsequent episodes. It has been previously suggested that using the predominant polarity can be useful for the selection of appropriate maintenance treatment with either antidepressants and/or mood stabilizers for depression, or mood stabilizers and/or antipsychotics for mania [41, 42]. However, there are major limitations to this approach. Baldessarini et al. [5] showed that upwards of 47% of patients with bipolar I disorder could not be characterized by predominant polarity, which significantly limits the utility of this concept. In addition, an individual patient's classification may

Table 1 Rates of suicide

Disorder	Attempted suicide	Completed suicide
General worldwide population	0.7 to 5% per year 0.8 to 2.7% lifetime prevalence	0.0036 to 0.037% per year Unknown lifetime prevalence
MDD	8% per year 31% lifetime prevalence	0.04% per year 10–15% lifetime prevalence
Bipolar I disorder	15% per year 33.9% lifetime prevalence	0.4 to 0.9% per year 15–20% lifetime prevalence

change over time, further complicating predictive validity and clinical utility [38•, 43]. Research is unclear on whether bipolar I disorder or bipolar II disorder has the higher rate of suicide [1•, 44, 45].

Many would argue that bipolar disorder remains underrecognized and underdiagnosed, contributing to undertreatment [24]. Subsequently, more than half of bipolar patients who complete suicide were not receiving treatment at the time of their death. Furthermore, the suicide attempts of bipolar disorder patients have higher lethality than any other psychiatric disorder [46]. The proportion of suicide attempts to completed suicide in bipolar disorder is 3:1, compared to 35:1 in the general population [26]. So, not only do bipolar patients carry a much greater burden of depression compared to other psychiatric disorders, they make more lethal attempts, which contribute significantly to the high rate of suicide completion.

Studies of Suicide Risk Factors in Bipolar Disorder

While the general suicide risk factors also apply to bipolar patients, there are some distinct disease-specific risk factors as well, defining these risk factors has been difficult (Table 2). Over the past few decades, studies investigating the risk factors for suicide in bipolar disorder have varied greatly in study design, changes in diagnostic criteria, and diagnostic switching. Moreover, assessing suicide requires a lot of effort with large samples, and the majority of persons will not commit suicide, even among patients with prior attempts. For that reason, suicide is a rare event, and, historically, investigating rare events within any population is problematic. Even a small change in the demographic variables in a sample from one study to the next can lead to conflicting results.

Gender, history of suicide attempt, suicidal ideation, family history of suicide, mood episodes, rapid cycling illness, age of

Table 2 Suicide risk factors in bipolar disorder

Sociodemographic factors	<ul style="list-style-type: none"> • Men have higher rates of completed suicide • Women have higher rates of attempted suicide • Caucasian • Marital status (single, widowed, divorced) • Living alone • No children • Younger age (<35 years), elderly age (>75 years) • Unemployment
Clinical history	<ul style="list-style-type: none"> • History of prior suicide attempt(s) • Family history of attempted or completed suicide(s) • Suicidal ideation • Predominant depressive polarity • Major depressive episode • Phase of illness: depression > mixed > dysphoric mania > pure mania > euthymia • Rapid cycling subtype • Earlier age of onset • Earlier stage of illness course • Longer duration of untreated illness • Number of previous depressive episodes • Previous hospitalization(s) • Concurrent medical comorbidity • Mood-incongruent psychotic symptoms
Psychiatric comorbidity	<ul style="list-style-type: none"> • Personality disorders: borderline, antisocial, histrionic, narcissistic
Genetic factors	<ul style="list-style-type: none"> • Noncoding RNA <i>LOC105374524</i> • Serotonin-related genes: <i>5-HTT</i>, <i>5-HT1–7</i>, <i>TPH1</i>, <i>TPH2</i> • Other genes: <i>AKT1</i>, <i>AKT1P</i>, <i>ADRA2</i>, <i>BDNF</i>, <i>COMT</i>, <i>CREB1</i>, <i>GSK3B</i>, <i>FOX03A</i>, and <i>MAPK1</i>
Other (needs further study)	<ul style="list-style-type: none"> • Alcohol and drug use disorders • Childhood abuse and neglect • Aggressive or impulsive behavior • Higher altitude • Dysfunctional personality traits • Poor social support

onset, episode polarity, polarity of first affective episode, history of trauma, drug abuse, personality disorders, and personality features, have all been studied as risk factors for suicide in bipolar disorder (Table 2) [24, 47•]. Conflicting results for gender as a risk factor in bipolar disorder are common. Some studies have shown that men tend to have higher rates of completed suicide, while women have higher rates of suicide attempts, especially at younger ages, indicating higher lethality of suicidal acts in men [48–50]. Other studies have found no gender difference in suicide attempts [51]. Although many studies have demonstrated that males have a higher rate of suicide, often using more violent means, there remains no clear difference between males and females [34, 49, 52–54].

One of the most robust predictors of suicide attempts and suicide completions in patients with bipolar disorder is a history of prior suicide attempts [24, 50, 53–56]. Prior suicide attempt increases the risk of completed suicide by 37-fold in bipolar patients [57], and at least half of suicides occur in individuals with prior attempts [46, 58]. Suicidal ideation has been associated with subsequent suicides and suicide attempts among bipolar disorder patients. Suicidal ideation itself varies from 14 to 59%, and is related to hopelessness, mixed depression, severe depression, psychotic symptoms, past suicide attempt, alcohol abuse, panic disorder symptoms, and earlier age of onset [24, 59, 60]. Suicidal ideation occurs in 79% of bipolar patients during the depressed phase, and is also significantly associated with mixed phases, both of which have a much stronger association than during mania [24, 61]. In bipolar disorder, a positive family history of attempted and completed suicide increase risk for suicide, especially in first-degree relatives [53, 54]. This is partly explained by the heritability of bipolar disorder itself (40%), as well as familial transmission of suicidal behavior [62].

Major depressive episodes alone are a significant risk factor for suicide in bipolar disorder, with the majority of attempted and completed suicides occurring during depressive phases. In addition, if the first mood episode has a predominant-depressive polarity, there is an eightfold greater risk for suicide attempt. Predominant-depressive polarity in subsequent episodes is associated with increased risk of suicidal acts and suicide attempts [5, 39, 41, 63]. Suicidal ideation and behavior is also relatively common in mixed episodes and dysphoric mania, with 26–55% of patients with dysphoric mania having suicidal ideation, and only 2–7% in patients with pure mania [24, 35, 52]. However, bipolar disorder patients attempt or commit suicide mostly during severe, pure, or mixed depressive episodes (78–80%), much less frequently during mixed affective episodes or dysphoric mania (11–20%), and very rarely during states of euphoric mania or euthymia (0–7%) [24, 64]. Severe, agitated and/or anxious major depression, especially with recurrent insomnia in the presence of a past suicide attempt is associated with the highest-risk for suicide in bipolar patients [24, 65]. The rapid

cycling subtype of bipolar disorder has also been identified as a risk factor for suicide attempts, with a 54% higher risk for attempted suicide, and higher intent and lethality compared to non-rapid cyclers [54, 66]. Other characteristics of the mood disorders have been associated with suicide, including an increased risk at the onset of illness during the first depressive episode, earlier stage in the illness course, longer duration of untreated illness, number of previous depressive episodes, previous hospitalizations, and concurrent medical comorbidity [28]. There is also an association with emergence of mood-incongruent psychotic symptoms and increased suicidal risk [67].

Age of onset of bipolar disorder has been associated with the risk for suicide attempt, with younger age at diagnosis associated with a higher risk [49, 54]. There is inconclusive evidence for the traditional alcohol and drug use disorders and nicotine use disorder as risk factors for suicide in bipolar disorder. Suicide risk is significantly increased with comorbid personality disorders, including the borderline, antisocial, histrionic, and narcissistic types. These personality disorders are associated with higher rates of severe mood episodes, environmental reactivity, and increased impulsivity, and aggressiveness [24]. Other risk factors, which have not been thoroughly studied, and likely contribute to suicidality, include childhood abuse and neglect [28], higher altitude [68•], dysfunctional personality traits [69, 70], marital status (single, widowed, divorced), poor social support, spirituality, and religiosity [10•]. Overall, the most consistent and robust risk factors for suicide in bipolar disorder across studies are a personal history of attempted suicide and a family history of attempted or completed suicide.

Assessment of the Suicidal Bipolar Patient

Clinical assessment of the suicidal bipolar patient should always be carried out at the earliest possible opportunity with direct clinical inquiry. There are general risk assessment tools that may allow physicians to identify high-risk patients and initiate treatments early and effectively (e.g., the Columbia-Suicide Severity Rating Scale (C-SSRS) [71], Columbia Classification Algorithm of Suicide Assessment (C-CASA) [72], The Tool for Assessment of Suicide Risk (TASR) [73], the Oxford Mental Illness and Suicide tool (OxMIS) [74], or the Modular Assessment of Risk for Imminent Suicide (MARIS) [75]). However, these tools should never be used as a replacement for thorough clinical assessment, even though there are no clearly defined criteria have been established to predict suicide risk in an individual patient. Currently, there are no validated suicide risk assessment tools specifically for bipolar disorder.

Suicide assessment should include a thorough psychiatric examination of mental status, focusing on mood, irritability,

the presence or absence of psychosis, and suicidal ideation and plans. Special attention is required to establish the nature, extent, and duration of suicidal ideation, and whether the patient has a plan; the method they intend to use; and the extent, nature, and lethality of previous suicide attempts; as well as the patient's access to lethal means [76]. In addition, investigation into the nature of the patient's affective temperament (depressive, cyclothymic, hyperthymic, irritable, and anxious) and personality traits could more clearly establish suicide risk [49]. Establishing possible protective factors, such as marriage, children, employment, and religious beliefs, can be equally as important as establishing risk factors. The patient's history of medication and treatment adherence will also contribute to treatment planning. The involvement of family members and/or close friends should be included as informants during the initial evaluation (providing consent has been obtained) to gather additional information and to prepare for treatment planning and follow-up care. If believed to pose a risk to him- or herself, the patient should be hospitalized.

For patients with an elevated risk of suicide treated on an outpatient basis, follow-up assessments should occur at regular intervals after the initial assessment, paying close attention to any change in clinical status and emergence of new symptoms (i.e., mixed episode). Patients with suicidal thoughts have typically had thoughts of suicide for a long period of time, and most patients are willing to discuss these openly. Therefore, the clinician should not avoid discussing suicide out of fear of provoking suicidal behavior or personal discomfort with the topic. This is an important issue that needs to be addressed with all patients, especially those with significant risk factors.

It is notable that a large proportion of individuals (regardless of diagnosis) who eventually complete suicide will have made contact with mental health services in the months preceding their death [26]. The risk of suicide is elevated in the first several weeks after discharge from a psychiatric hospital [77]. It has been estimated that as much as 75–83% of individuals who completed suicide had been in contact with a physician within the previous 1 year. Additionally, only 46% had seen a mental health professional within a month and 36% in the week before death. This makes the detection of individuals at acute risk for suicide extremely difficult, and suggests that effective interventions for many, and perhaps most, suicidal patients may not occur.

Management of the Suicidal Bipolar Patient

Bipolar patients brought into the emergency department after suicidal threats or non-harmful attempts present one of the greatest challenges to psychiatrists. Conservatively, the best course of management is to admit such patients to a psychiatric inpatient unit for protection and treatment. In general, any

patient with suicidal ideation or attempt and depression who is psychotic, intoxicated, cannot attend to daily needs, or whose well-being is in doubt by the clinician should be admitted for observation and treatment. In some cases, a court order will be needed to hospitalize the patient.

Pharmacotherapy

The first step in the management of bipolar disorder is to confirm the diagnosis, because the therapeutic approach differs depending on the phase of illness. In general, mood stabilizers and antipsychotics are the mainstay of acute management of mania and depression [1, 49, 78]. Lithium has long been known to reduce rates of suicide attempts and completions in depressed and bipolar patients. Multiple randomized controlled trials and meta-analyses, as well as decades of clinical experience, have shown that lithium significantly reduces the risk of self-harm and suicide in unipolar depression and bipolar depression [25, 79–82]. In one study of 50,000 bipolar patients, lithium was found to reduce the rate of completed suicide and other suicide-related events by 14% relative to treatment with valproate [81••]. However, lithium is not an acute intervention, rather a prophylaxis against suicide, and can be lethal in overdose. Long-term lithium use decreases the risk of death by 60–80% [80, 83]. Lithium non-adherence increases suicidal risk, and lithium discontinuation increases the risk of death by 13-fold [63, 84]. A more rapid treatment of suicidality is possible with intravenous and intranasal ketamine for bipolar patients [85–87], but ketamine is not widely available.

As for other mood stabilizers, after investigating 199 clinical trials of 11 antiepileptic drugs (AEDs; carbamazepine, divalproex, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, and zonisamide) for three different indications, including epilepsy, pain, bipolar disorder, and other psychiatric disorders, the Food and Drug Administration (FDA) has reported that there is an increased risk of suicide. However, this report has been thoroughly questioned over the last decade, and studies have shown that AEDs do not increase the risk of suicide attempts or completed suicide in patients with bipolar disorder [88, 89]. Moreover, valproate, lamotrigine, and carbamazepine have been shown to have a possible anti-suicidal effect, although less than what is reported for lithium [55, 90, 91].

Although antidepressants significantly reduce the risk of suicide in depressed patients with long-term treatment, no antidepressant medication has demonstrated an anti-suicidal effect [77, 92]. In fact, some studies have suggested that antidepressant treatment might increase suicidality in a subgroup of bipolar patients, which has not been shown for completed suicides [28]. There also remains a concern that antidepressant medications can worsen the course of disease by provoking a switch into a hypomanic, manic, or mixed mood state, or

inducing agitation in mixed episodes, possibly contributing to suicidal behavior [93]. However, the International Society for Bipolar Disorders (ISBD) task force acknowledged that some bipolar patients might benefit from antidepressant medication, with bupropion having the lowest risk of switching, only as long as they are prescribed as an adjunct to mood stabilizers [94].

Quetiapine, lurasidone, and olanzapine/fluoxetine are the antipsychotic medications of choice for treatment of bipolar depression. Some atypical antipsychotics (aripiprazole, olanzapine, and quetiapine) may have an acute antidepressant effect and long-term mood-stabilizing effect in patients with bipolar disorder, but there is no specific evidence for an anti-suicidal effect [26, 95]. Clozapine is the only antipsychotic medication that has FDA approved for use in the reduction of recurrent suicidal behavior. However, this is limited only to patients with schizophrenia or schizoaffective disorder, and there is currently no indication for its use in bipolar disorder. In addition, current evidence suggests that antipsychotic medications should only be used in addition to mood stabilizers for breakthrough hypomanic or manic episodes, and discontinued as soon as clinically feasible due to the long-term metabolic side effects [96].

Electroconvulsive therapy (ECT) is effective in eliminating acute suicidal risk in severely depressed and deeply suicidal adult patients [83, 97, 98]. ECT has also been considered as the treatment of choice in emergency situations for patients with high suicide risk [99]. Compared with current pharmacotherapy treatments, ECT has superior anti-suicidal effects in patients with both unipolar and bipolar depression [100]. However, the long-term effect of ECT for the treatment of suicidality in patients with bipolar disorder is unknown [49, 101].

Transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS) are both approved as therapy for treatment-resistant major depressive disorder, with a possible short-term decrease in suicide risk. Although studies have shown a potential benefit from the use of TMS and rTMS in bipolar depression, there remains a theoretical risk of switching to hypomania or mania, and TMS is not currently approved by the FDA for bipolar depression [102–104].

Vagal nerve stimulation (VNS) is approved as adjunctive therapy for treatment-resistant major depressive disorder, but only if the patient has failed 4 or more different medications [105]. There is little evidence for the use of VNS in bipolar depression, and it is not currently FDA approved for this indication.

Psychotherapy

While the efficacy of dialectical behavioral therapy in reducing the frequency of suicide attempts and deliberate self-harm has been shown in several studies in patients with borderline

personality disorder [83, 106, 107], the modality has not been used in patients with bipolar disorder. In general, psychotherapy and other psychological treatments are used as adjuncts to pharmacotherapy in the treatment of suicidal patients [83, 108]. However, only a small number of studies have investigated psychological treatment for suicidality in bipolar disorder, and no clear benefit has been shown [26, 83, 108].

Prediction and Prevention of Suicide in the Bipolar Patient

The natural history of bipolar disorder often includes periods of remission; however, recurrence is common in bipolar patients, particularly with poor treatment adherence. Predicting recurrent episodes is extremely difficult, and there are currently no validated clinical or biological measures that can be used in patients with bipolar disorder.

Genetics

The ultimate goal of genetic studies on suicide is to translate underlying biological mechanisms into treatments and prevention strategies. Genetic risk factors have been consistently found to play a significant role in suicide in bipolar disorder, as demonstrated by primary studies and also supported by twin, family and adoption studies [44, 46, 47•, 67]. Candidate gene studies have found evidence for the role of genetic variation in suicidality, but many of these studies have had mixed results [26]. Serotonin-related genes (transporters and receptors), such as *5-HTT* and *5-HT1-7*, and tryptophan hydroxylase genes, *TPH1* and *TPH2*, have shown a significant association with the risk of suicidal behavior. Many other genes, such as *AKT1*, *AKT1P*, *ADRA2*, *BDNF*, *COMT*, *CREB1*, *GSK3B*, *FOXO3A*, and *MAPK1*, have all been associated with suicidal behavior [26, 109–111]. Most recently, the largest genome-wide association study (GWAS) to date, found 3 genome-wide significant loci for increased risk of suicide attempt: one for major depressive disorder, one for bipolar disorder, and one for mood disorders [112]. For bipolar disorder, this was an insertion-deletion polymorphism on chromosome 4, an intronic variant in the noncoding RNA *LOC105374524*.

Neuroimaging

There is some evidence to suggest that white matter hyperintensities (WMH) in the brain of patients with bipolar disorder may increase suicidal risk [113–116]. However, these results could be obscured by the correlation between increased WMH volume in relation to the diagnosis of bipolar disorder itself, and associated with disease burden, not directly related to the degree of suicidal risk [117].

Endocrinology

Altered functioning of the hypothalamic-pituitary-adrenal (HPA) axis has been reported in suicidal behavior in bipolar disorder [118]. However, many studies of HPA axis function in bipolar disorder have not specifically examined the potential effects of suicidal behavior, and studies showing an association between HPA axis activity and suicidality have been mixed [119–121]. There is also no current clinical indication for the benefit of measuring salivary/plasma cortisol levels or performing a dexamethasone suppression test in patients with bipolar disorder to assess suicidal risk.

Conclusion

Bipolar disorder carries a high burden of disability and has the highest risk of death by suicide compared with other psychiatric disorders. Suicide is difficult to predict, but certain risk factors, including history of past suicide attempt, and family history of suicide attempt or suicide completion, as well as a predominant depressive polarity, can be used to assess risk in patients with bipolar disorder. Early intervention and treatment of bipolar depression with mood stabilizers and/or antipsychotics, along with close observation and follow-up is the most effective way to mitigate suicide in these patients. Lithium may offer an advantage of lowering the patient's risk for suicidal behavior. ECT could also provide a fast and effective means of treating suicidality in bipolar disorder. Close involvement of family members or friends, a supportive social environment, as well as psychological support can provide further benefit. There are currently no validated genetic, neuroimaging, or clinical biomarkers that can be used for the assessment of suicide risk.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. • Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. *Lancet*. 2016;387:1561–72. **This is a comprehensive review of bipolar disorder and emphasizes the importance of accurate diagnosis.**

2. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub
3. Alonso J, Petukhova M, Vilagut G, Chatterji S, Heeringa S, Üstün TB, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. *Mol Psychiatry*. 2011;16:1234–46.
4. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. *Arch Gen Psychiatry*. 2007;64:543–52.
5. Baldessarini RJ, Undurraga J, Vázquez GH, Tondo L, Salvatore P, Ha K, et al. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. *Acta Psychiatr Scand*. 2012;125:293–302.
6. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62:617–27.
7. Grande I, Goikolea JM, de Dios C, González-Pinto A, Montes JM, Saiz-Ruiz J, et al. Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data). *Acta Psychiatr Scand*. 2013;127:403–11.
8. Martínez-Aran A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M, et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. *Bipolar Disord*. 2007;9:103–13.
9. Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. *J Clin Psychiatry*. 2010;71:e14.
10. • da Costa LS, Alencar ÁP, PJN N, et al. Risk factors for suicide in bipolar disorder: a systematic review. *J Affect Disord*. 2015;170: 237–54. **A useful review of risk factors for suicide in bipolar disorder.**
11. de Abreu LN, Nery FG, Harkavy-Friedman JM, de Almeida KM, Gomes BC, Oquendo MA, et al. Suicide attempts are associated with worse quality of life in patients with bipolar disorder type I. *Compr Psychiatry*. 2012;53:125–9.
12. Michalak EE, Yatham LN, Kolesar S, Lam RW. Bipolar disorder and quality of life: a patient-centered perspective. *Qual Life Res*. 2006;15:25–37.
13. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. *Health Qual Life Outcomes*. 2005;3:72.
14. WHO, World Health Organization (1993) The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. World Health Organization
15. Berk M, Dodd S, Callaly P, Berk L, Fitzgerald P, de Castella AR, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. *J Affect Disord*. 2007;103:181–6.
16. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. *Am J Psychiatry*. 2001;158:1265–70.
17. (2018) WHO mortality database. In: World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/suicide>. Accessed 20 Sept 2019
18. Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. *Bipolar Disord*. 2013;15:457–90.
19. Blasco-Fontecilla H, Artieda-Urrutia P, de Leon J. A proposal for using the ratio of attempted to completed suicides across several countries worldwide. *Epidemiol Psychiatr Sci*. 2019;28:473–7.
20. Nock MK, Borges G, Bromet EJ, Alonso J, Angermeyer M, Beautrais A, et al. Cross-national prevalence and risk factors for

- suicidal ideation, plans and attempts. *Br J Psychiatry*. 2008;192: 98–105.
21. Dong M, Zeng L-N, Lu L, Li X-H, Ungvari GS, Ng CH, et al. Prevalence of suicide attempt in individuals with major depressive disorder: a meta-analysis of observational surveys. *Psychol Med*. 2019;49:1691–704.
 22. Baldessarini RJ, Tondo L, Pinna M, Nuñez N, Vázquez GH. Suicidal risk factors in major affective disorders. *Br J Psychiatry*. 2019;1–6.
 23. Dong M, Lu L, Zhang L, Zhang Q, Ungvari GS, Ng CH, et al. Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies. *Epidemiol Psychiatr Sci*. 2019;29:e63 1–9.
 24. Gonda X, Pompili M, Serafini G, Montebovi F, Campi S, Dome P, et al. Suicidal behavior in bipolar disorder: epidemiology, characteristics and major risk factors. *J Affect Disord*. 2012;143:16–26.
 25. Sadock BJ, Sadock VA, Ruiz P (2015) Kaplan & Sadock's synopsis of psychiatry, 11th ed. Wolters Kluwer.
 26. Plans L, Barrot C, Nieto E, Rios J, Schulze TG, Papiol S, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. *J Affect Disord*. 2019;242: 111–22.
 27. Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. *Arch Gen Psychiatry*. 2001;58:844–50.
 28. McIntyre RS, Muzina DJ, Kemp DE, Blank D, Woldeyohannes HO, Lofchy J, et al. Bipolar disorder and suicide: research synthesis and clinical translation. *Curr Psychiatry Rep*. 2008;10:66–72.
 29. Takizawa T. Suicide due to mental diseases based on the vital statistics survey death form. *Nihon Koshu Eisei Zasshi*. 2012;59: 399–406.
 30. Hoyer EH, Mortensen PB, Olesen AV. Mortality and causes of death in a total national sample of patients with affective disorders admitted for the first time between 1973 and 1993. *Br J Psychiatry*. 2000;176:76–82.
 31. Sani G, Tondo L, Koukopoulos A, Reginaldi D, Kotzalidis GD, Koukopoulos AE, et al. Suicide in a large population of former psychiatric inpatients. *Psychiatry Clin Neurosci*. 2011;65:286–95.
 32. Osborn D, Levy G, Nazareth I, King M. Suicide and severe mental illnesses. Cohort study within the UK general practice research database. *Schizophr Res*. 2008;99:134–8.
 33. Goldstein TR, Ha W, Axelson DA, Goldstein BI, Liao F, Gill MK, et al. Predictors of prospectively examined suicide attempts among youth with bipolar disorder. *Arch Gen Psychiatry*. 2012;69:1113–22.
 34. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. *CNS Drugs*. 2003;17:491–511.
 35. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. *CNS Spectr*. 2006;11:465–71.
 36. Altamura AC, Dell'Osso B, Berlin HA, Buoli M, Bassetti R, Mundo E. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. *Eur Arch Psychiatry Clin Neurosci*. 2010;260:385–91.
 37. Daban C, Colom F, Sanchez-Moreno J, García-Amador M, Vieta E. Clinical correlates of first-episode polarity in bipolar disorder. *Compr Psychiatry*. 2006;47:433–7.
 38. Pallaskorpi S, Suominen K, Rosenström T, et al. Predominant polarity in bipolar I and II disorders: a five-year follow-up study. *J Affect Disord*. 2019;246:806–13. **This 5-year follow up study concluded that predominant polarity has predictive value for illness course, including suicidal behavior.**
 39. Colom F, Vieta E, Daban C, Pacchiarotti I, Sánchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. *J Affect Disord*. 2006;93:13–7.
 40. Angst J, Felder W, Frey R, Stassen HH. The course of affective disorders. *Archiv für Psychiatrie und Nervenkrankheiten Vereinigt mit Zeitschrift für die Gesamte Neurologie und Psychiatrie*. 1978;226:57–64.
 41. Carvalho AF, Quevedo J, McIntyre RS, Soeiro-de-Souza MG, Fountoulakis KN, Berk M, et al. Treatment implications of predominant polarity and the polarity index: a comprehensive review. *Int J Neuropsychopharmacol*. 2014. <https://doi.org/10.1093/ijnp/pyu079>.
 42. Chaudhury SR, Grunebaum MF, Galfalvy HC, Burke AK, Sher L, Parsey RV, et al. Does first episode polarity predict risk for suicide attempt in bipolar disorder? *J Affect Disord*. 2007;104:245–50.
 43. Belizario GO, Silva M, Lafer B. Impact of predominant polarity on long-term outcome in bipolar disorder: a 7-year longitudinal cohort study. *J Affect Disord*. 2018;241:37–40.
 44. Tondo L, Lepri B, Baldessarini RJ. Suicidal risks among 2826 Sardinian major affective disorder patients. *Acta Psychiatr Scand*. 2007;116:419–28.
 45. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. *Bipolar Disord*. 2010;12:1–9.
 46. Dennehy EB, Marangell LB, Allen MH, Chessick C, Wisniewski SR, Thase ME. Suicide and suicide attempts in the systematic treatment enhancement program for bipolar disorder (STEP-BD). *J Affect Disord*. 2011;133:423–7.
 47. Schaffer A, Isometsä ET, Tondo L, et al. International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. *Bipolar Disord*. 2015;17:1–16. **This meta-analysis reports on risk factors for suicidal behavior and completed suicide. The latter is associated with male sex and a family history of suicide.**
 48. Simon GE, Hunkeler E, Fireman B, Lee JY, Savarino J. Risk of suicide attempt and suicide death in patients treated for bipolar disorder. *Bipolar Disord*. 2007;9:526–30.
 49. Pompili M, Rihmer Z, Innamorati M, Lester D, Girardi P, Tatarelli R. Assessment and treatment of suicide risk in bipolar disorders. *Expert Rev Neurother*. 2009;9:109–36.
 50. Coryell W, Kriener A, Butcher B, Nurnberger J, McMahon F, Berrettini W, et al. Risk factors for suicide in bipolar I disorder in two prospectively studied cohorts. *J Affect Disord*. 2016;190: 1–5.
 51. Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy S, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. *J Clin Psychiatry*. 2003;64:506–15.
 52. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. *Arch Suicide Res*. 2005;9:279–300.
 53. Cassidy F. Risk factors of attempted suicide in bipolar disorder. *Suicide Life Threat Behav*. 2011;41:6–11.
 54. Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. *J Clin Psychiatry*. 2005;66:693–704.
 55. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. *JAMA*. 2003;290:1467–73.
 56. Marangell LB, Bauer MS, Dennehy EB, Wisniewski SR, Allen MH, Miklowitz DJ, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. *Bipolar Disord*. 2006;8:566–75.
 57. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. *Br J Psychiatry*. 1997;170:205–28.
 58. Owen R, Gooding P, Dempsey R, Jones S. A qualitative investigation into the relationships between social factors and suicidal thoughts and acts experienced by people with a bipolar disorder diagnosis. *J Affect Disord*. 2015;176:133–40.

59. Bottlender R, Jäger M, Strauss A, Möller HJ. Suicidality in bipolar compared to unipolar depressed inpatients. *Eur Arch Psychiatry Clin Neurosci.* 2000;250:257–61.
60. Johnson SL, McMurrich SL, Yates M. Suicidality in bipolar I disorder. *Suicide Life Threat Behav.* 2005;35:681–9.
61. Dilsaver SC, Chen YW, Swann AC, Shoib AM, Krajewski KJ. Suicidality in patients with pure and depressive mania. *Am J Psychiatry.* 1994;151:1312–5.
62. McGuffin P, Perroud N, Uher R, Butler A, Aitchison KJ, Craig I, et al. The genetics of affective disorder and suicide. *Eur Psychiatry.* 2010;25:275–7.
63. Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. *Bipolar Disord.* 2006;8:618–24.
64. Black DW, Winokur G, Nasrallah A. Suicide in subtypes of major affective disorder. A comparison with general population suicide mortality. *Arch Gen Psychiatry.* 1987;44:878–80.
65. Rihmer Z. Suicide risk in mood disorders. *Curr Opin Psychiatry.* 2007;20:17–22.
66. Coryell W, Solomon D, Turvey C, Keller M, Leon AC, Endicott J, et al. The long-term course of rapid-cycling bipolar disorder. *Arch Gen Psychiatry.* 2003;60:914–20.
67. Tsai S-YM, Kuo C-J, Chen C-C, Lee H-C. Risk factors for completed suicide in bipolar disorder. *J Clin Psychiatry.* 2002;63:469–76.
68. Huber RS, Coon H, Kim N, Renshaw PF, Kondo DG. Altitude is a risk factor for completed suicide in bipolar disorder. *Med Hypotheses.* 2014;82:377–81. **This study presents data supporting the intriguing possibility that altitude is a risk factor for suicide in bipolar disorder.**
69. Pompili M, Rihmer Z, Akiskal HS, Innamorati M, Iliceto P, Akiskal KK, et al. Temperament and personality dimensions in suicidal and nonsuicidal psychiatric inpatients. *Psychopathology.* 2008;41:313–21.
70. Rihmer A, Rozsa S, Rihmer Z, Gonda X, Akiskal KK, Akiskal HS. Affective temperaments, as measured by TEMPS-A, among nonviolent suicide attempts. *J Affect Disord.* 2009;116:18–22.
71. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry.* 2011;168:1266–77.
72. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. *Am J Psychiatry.* 2007;164:1035–43.
73. Chehil S, Kutcher SP (2012) Suicide risk management: a manual for health professionals. Wiley.
74. Fazel S, Wolf A, Larsson H, Mallett S, Fanshawe TR. The prediction of suicide in severe mental illness: development and validation of a clinical prediction rule (OxMIS). *Transl Psychiatry.* 2019;9:98.
75. Hawes M, Yaseen Z, Briggs J, Galynker I. The Modular Assessment of Risk for Imminent Suicide (MARIS): a proof of concept for a multi-informant tool for evaluation of short-term suicide risk. *Compr Psychiatry.* 2017;72:88–96.
76. Saunders KEA, Hawton K. Clinical assessment and crisis intervention for the suicidal bipolar disorder patient. *Bipolar Disord.* 2013;15:575–83.
77. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. *J Affect Disord.* 2002;68:167–81.
78. Grande I, Vieta E. Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics? *CNS Drugs.* 2015;29:221–7.
79. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. *Am J Psychiatr.* 2005;162:1805–19.
80. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ.* 2013;346:f3646.
81. Song J, Sjölander A, Joas E, Bergen SE, Runeson B, Larsson H, et al. Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. *Am J Psychiatry.* 2017;174:795–802. **A large study from Sweden again confirms the benefit of lithium carbonate treatment in reducing risk of suicide-related events in bipolar disorder patients.**
82. Schatzberg AF, Charles DeBattista DMH (2019) Schatzberg's manual of clinical psychopharmacology, 9th Edition. American Psychiatric Pub.
83. Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, et al. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. *Eur Psychiatry.* 2012;27:129–41.
84. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. *J Clin Psychiatry.* 1999;60(Suppl 2):77–84 discussion 111–6.
85. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. *Am J Psychiatry.* 2018;175:150–8.
86. Zhan Y, Zhang B, Zhou Y, Zheng W, Liu W, Wang C, et al. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. *J Affect Disord.* 2019;251:205–12.
87. Ballard ED, Yarrington JS, Farmer CA, Richards E, Machado-Vieira R, Kadriu B, et al. Characterizing the course of suicidal ideation response to ketamine. *J Affect Disord.* 2018;241:86–93.
88. Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. *Arch Gen Psychiatry.* 2009;66:1354–60.
89. Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, et al. Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. *Am J Psychiatry.* 2012;169:285–91.
90. Patormo E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. *JAMA.* 2010;303:1401–9.
91. Yerevanian BI, Koek RJ, Mintz J, Akiskal HS. Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants. *J Affect Disord.* 2007;103:13–21.
92. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. *Am J Psychiatry.* 2007;164:1044–9.
93. Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, et al. Genetics of emergent suicidality during antidepressive treatment—data from a naturalistic study on a large sample of inpatients with a major depressive episode. *Eur Neuropsychopharmacol.* 2013;23:663–74.
94. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. *Am J Psychiatry.* 2013;170:1249–62.

95. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. *Bipolar Disord.* 2009;11:225–55.
96. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior Part 3: impact of antipsychotics. *J Affect Disord.* 2007;103:23–8.
97. Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. *J ECT.* 2014;30:5–9.
98. Prudic J, Sackeim HA. Electroconvulsive therapy and suicide risk. *J Clin Psychiatry.* 1999;60(Suppl 2):104–10 discussion 111–6.
99. American Psychiatric Association (2008) The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (A Task Force Report of the American Psychiatric Association). American Psychiatric Pub
100. Liang C-S, Chung C-H, Ho P-S, Tsai C-K, Chien W-C. Superior anti-suicidal effects of electroconvulsive therapy in unipolar disorder and bipolar depression. *Bipolar Disord.* 2018;20:539–46.
101. Chiles JA, Strosahl KD, Roberts LW (2018) Clinical manual for assessment and treatment of suicidal patients. American Psychiatric Pub.
102. Dell'Osso B, Mundo E, D'Urso N, et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. *Bipolar Disord.* 2009;11:76–81.
103. Tamas RL, Menkes D, El-Mallakh RS. Stimulating research: a prospective, randomized, double-blind, sham-controlled study of slow transcranial magnetic stimulation in depressed bipolar patients. *J Neuropsychiatr Clin Neurosci.* 2007;19:198–9.
104. Carnell BL, Clarke P, Gill S, Galletly CA. How effective is repetitive transcranial magnetic stimulation for bipolar depression? *J Affect Disord.* 2017;209:270–2.
105. Carreno FR, Frazer A. Vagal nerve stimulation for treatment-resistant depression. *Neurotherapeutics.* 2017;14:716–27.
106. Stanley B, Brodsky B, Nelson JD, Dulit R. Brief dialectical behavior therapy (DBT-B) for suicidal behavior and non-suicidal self injury. *Arch Suicide Res.* 2007;11:337–41.
107. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. *Arch Gen Psychiatry.* 2006;63:757–66.
108. Rudd MD, David Rudd M, Williams B, Trotter DRM (2009) The psychological and behavioural treatment of suicidal behaviour. Oxford Textb Suicidol Suicide Prev 428–438.
109. Magno LAV, Santana CVN, Sacramento EK, Rezende VB, Cardoso MV, Maurício-da-Silva L, et al. Genetic variations in FOXO3A are associated with bipolar disorder without conferring vulnerability for suicidal behavior. *J Affect Disord.* 2011;133:633–7.
110. Magno LAV, Miranda DM, Neves FS, Pimenta GJ, Mello MP, De Marco LA, et al. Association between AKT1 but not AKTIP genetic variants and increased risk for suicidal behavior in bipolar patients. *Genes Brain Behav.* 2010;9:411–8.
111. Mirkovic B, Laurent C, Podlipski M-A, Frebourg T, Cohen D, Gerardin P. Genetic association studies of suicidal behavior: a review of the past 10 years, progress, limitations, and future directions. *Front Psychiatry.* 2016;7:158.
112. Mullins N, Bigdely TB, Børglum AD, Coleman JRI, Demontis D, Mehta D, et al. GWAS of suicide attempt in psychiatric disorders and association with major depression polygenic risk scores. *Am J Psychiatry.* 2019;176:651–60.
113. Taylor WD, Payne ME, Krishnan KR, Wagner HR, Provenzale JM, Steffens DC, et al. Evidence of white matter tract disruption in MRI hyperintensities. *Biol Psychiatry.* 2001;50:179–83.
114. Pompili M, Innamorati M, Mann JJ, Oquendo MA, Lester D, del Casale A, et al. Periventricular white matter hyperintensities as predictors of suicide attempts in bipolar disorders and unipolar depression. *Prog Neuro-Psychopharmacol Biol Psychiatry.* 2008;32:1501–7.
115. Grangeon MC, Seixas C, Quarantini LC, Miranda-Scippa A, Pompili M, Steffens DC, et al. White matter hyperintensities and their association with suicidality in major affective disorders: a meta-analysis of magnetic resonance imaging studies. *CNS Spectr.* 2010;15:375–81.
116. Pompili M, Ehrlich S, De Pisa E, et al. White matter hyperintensities and their associations with suicidality in patients with major affective disorders. *Eur Arch Psychiatry Clin Neurosci.* 2007;257:494–9.
117. Tighe SK, Reading SA, Rivkin P, Caffo B, Schweizer B, Pearson G, et al. Total white matter hyperintensity volume in bipolar disorder patients and their healthy relatives. *Bipolar Disord.* 2012;14:888–93.
118. Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, et al. The HPA axis in bipolar disorder: systematic review and meta-analysis. *Psychoneuroendocrinology.* 2016;63:327–42.
119. Kamali M, Saunders EFH, Prossin AR, Brucksch CB, Harrington GJ, Langenecker SA, et al. Associations between suicide attempts and elevated bedtime salivary cortisol levels in bipolar disorder. *J Affect Disord.* 2012;136:350–8.
120. Black DW, Monahan PO, Winokur G. The relationship between DST results and suicidal behavior. *Ann Clin Psychiatry.* 2002;14:83–8.
121. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. *Psychiatr Clin North Am.* 2005;28:469–80.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.